Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase1b/2 Study Combining Hepatic Percutaneous Perfusion With Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma

NCT04283890 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT04283890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04283890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase1b/2 Study Combining Hepatic Percutaneous Perfusion With Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma
Lead sponsor
Leiden University Medical Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 4, 2019
Completion date
December 31, 2029
Enrollment
83 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

uveal melanoma, metastatic